Real-World Evidence

20: Real-world Clinical Outcomes of Patients (pts) with Metastatic Renal Cell Carcinoma (mRCC) Receiving Pembrolizumab + Axitinib (P+A) vs Ipilimumab + Nivolumab (I+N)

21: Short-Term Outcomes of Active Surveillance for Small Renal Masses in Patients With End-Stage Renal Disease and Immunosuppression

22: Healthcare resource utilization (HCRU) and costs in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line (LOT1) pembrolizumab + axitinib (P+A) or ipilimumab + nivolumab (I+N)

23: Real-world Assessment of Changing Treatment Patterns and sequence for patients with Metastatic Renal Cell Carcinoma (mRCC) in the first-line (1L) setting

24: Depth of response associated with first-line immunotherapy-based combinations in metastatic clear cell renal cell carcinoma.

25: Clinical manifestations of Birt-Hogg-Dube Syndrome in a large clinical cohort